Laurion Capital Management’s Antares Pharma, Inc. ATRS Stock Holding History

Laurion Capital Management’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-483,406	Closed	-$1.37M	–	1956
2017 Q1	$1.37M	Buy	+483,406	New	+$1.16M	0.01%	677
2016 Q3	–	Sell	-445,200	Closed	-$467K	–	1153
2016 Q2	$467K	Buy	+445,200	New	+$430K	0.01%	584

Other funds holding ATRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Laurion Capital Management's ATRS Position: Q2 2017 in Review

Laurion Capital Management sold out of Antares Pharma, Inc. (ATRS) in Q2 2017, closing a stake of 483,406 shares — an estimated $1.37M sold.

Laurion Capital Management first reported a position in ATRS in Q2 2016 and held it in 2 quarters. The position peaked at $1.37M in Q1 2017. 103 funds tracked by Wall St. Rank hold ATRS as of Q2 2017.

Laurion Capital Management reported no remaining Antares Pharma, Inc. position as of Q2 2017 after selling out during the quarter.
Laurion Capital Management sold 483,406 Antares Pharma, Inc. shares in Q2 2017, an estimated $1.37M.
Laurion Capital Management first reported a position in Antares Pharma, Inc. in Q2 2016 and held it in 2 quarters.
Laurion Capital Management's Antares Pharma, Inc. position peaked at $1.37M in Q1 2017.
103 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2017.

Based on Laurion Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.